184 related articles for article (PubMed ID: 32401100)
21. Diagnostic Value of Serum-Soluble Interleukin 2 Receptor Levels vs Angiotensin-Converting Enzyme in Patients With Sarcoidosis-Associated Uveitis.
Groen-Hakan F; Eurelings L; ten Berge JC; van Laar J; Ramakers CRB; Dik WA; Rothova A
JAMA Ophthalmol; 2017 Dec; 135(12):1352-1358. PubMed ID: 29121154
[TBL] [Abstract][Full Text] [Related]
22. The soluble interleukin-2 receptor predicts mortality in older hospitalized men.
Rosenthal AJ; McMurtry CT; Sanders KM; Jacobs M; Thompson D; Adler RA
J Am Geriatr Soc; 1997 Nov; 45(11):1362-4. PubMed ID: 9361663
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
[TBL] [Abstract][Full Text] [Related]
24. Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse Events.
Takai R; Funakoshi Y; Suto H; Nagatani Y; Imamura Y; Toyoda M; Yakushijin K; Kiyota N; Harada KI; Yamashita K; Kakeji Y; Minami H
Anticancer Res; 2021 Feb; 41(2):1021-1026. PubMed ID: 33517310
[TBL] [Abstract][Full Text] [Related]
25. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
26. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
27. Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?
Buccheri G; Marino P; Preatoni A; Ferrigno D; Moroni GA
Chest; 1991 Jun; 99(6):1433-7. PubMed ID: 2036827
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo.
Merkel PA; Dooley MA; Dawson DV; Pisetsky DS; Polisson RP
J Rheumatol; 1996 Nov; 23(11):1856-61. PubMed ID: 8923356
[TBL] [Abstract][Full Text] [Related]
29. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of sIL-2R levels in B-cell lymphomas.
Yoshida N; Oda M; Kuroda Y; Katayama Y; Okikawa Y; Masunari T; Fujiwara M; Nishisaka T; Sasaki N; Sadahira Y; Mihara K; Asaoku H; Matsui H; Seto M; Kimura A; Arihiro K; Sakai A
PLoS One; 2013; 8(11):e78730. PubMed ID: 24236041
[TBL] [Abstract][Full Text] [Related]
31. High Level of Serum Soluble Interleukin-2 Receptor Is Associated With Poor Survival in Patients With First Relapsed or Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified: A Retrospective Study.
Morita-Fujita M; Katoh D; Shimomura Y; Ishikawa T
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e337-e342. PubMed ID: 31053551
[TBL] [Abstract][Full Text] [Related]
32. Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).
Kitagawa J; Hara T; Tsurumi H; Goto N; Kanemura N; Yoshikawa T; Kasahara S; Yamada T; Sawada M; Takahashi T; Shimizu M; Takami T; Moriwaki H
J Cancer Res Clin Oncol; 2009 Jan; 135(1):53-9. PubMed ID: 18592269
[TBL] [Abstract][Full Text] [Related]
33. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
[TBL] [Abstract][Full Text] [Related]
34. Relationship between serum levels of soluble interleukin-2 receptor and various disease parameters in patients with squamous cell carcinoma of the esophagus.
Oka M; Hazama S; Takahashi M; Yamamoto K; Abe T; Yoshino S; Hayashi H; Tangoku A
Hepatogastroenterology; 1999; 46(28):2254-9. PubMed ID: 10521976
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma.
Janik JE; Morris JC; Pittaluga S; McDonald K; Raffeld M; Jaffe ES; Grant N; Gutierrez M; Waldmann TA; Wilson WH
Blood; 2004 Nov; 104(10):3355-7. PubMed ID: 15205267
[TBL] [Abstract][Full Text] [Related]
36. Langerhans cell histiocytosis in children: does soluble interleukin-2-receptor correlate with both disease extent and activity?
Schultz C; Klouche M; Friedrichsdorf S; Richter N; Kroehnert B; Bucsky P
Med Pediatr Oncol; 1998 Aug; 31(2):61-5. PubMed ID: 9680928
[TBL] [Abstract][Full Text] [Related]
37. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
[TBL] [Abstract][Full Text] [Related]
38. Soluble interleukin 2 receptor (sIL-2R) levels in renal transplant recipients.
Mehta R; Shah G; Adler W; Kittur D
Clin Transplant; 2004; 18 Suppl 12():67-71. PubMed ID: 15217411
[TBL] [Abstract][Full Text] [Related]
39. Soluble IL-2 receptor: a biomarker for assessing myositis activity.
Tournadre A; Dubost JJ; Soubrier M; Ruivard M; Souteyrand P; Schmidt J; Clavelou P; Tridon A; Ristori JM
Dis Markers; 2014; 2014():472624. PubMed ID: 24648607
[TBL] [Abstract][Full Text] [Related]
40. Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome.
Ogata K; Yokose N; An E; Kamikubo K; Tamura H; Dan K; Sakamaki H; Onozawa Y; Hamaguchi H; Nomura T
Br J Haematol; 1996 Apr; 93(1):45-52. PubMed ID: 8611474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
